EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)

Hypofractionated Radiotherapy followed by Hypofractionated Boost with weekly concurrent chemotherapy for Unresectable Stage III Non–Small Cell Lung Cancer: Results of A Prospective Phase II Study (GASTO-1049)

Rui Zhou, Bo Qiu, Mai Xiong, YiMei Liu, KangQiang Peng, YiFeng Luo, DaQuan Wang, FangJie Liu, NaiBin Chen, JinYu Guo, Jun Zhang, XiaoYan Huang und 2 weitere

International Journal of Radiation Oncology*Biology*Physics · 2023

DOI: 10.1016/j.ijrobp.2023.04.021 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift International Journal of Radiation Oncology*Biology*Physics, 2023. Verfasst von Rui Zhou und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China; State Key Laboratory of Oncology in South China, Guangzhou,…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Radiation Injuries, Esophagitis. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 45 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: We launched a prospective phase 2 clinical trial to explore the safety and efficacy of hypofractionated radiation therapy (hypo-RT) followed by hypofractionated boost (hypo-boost) combined with concurrent weekly chemotherapy in patients with unresectable locally advanced non-small cell lung cancer (LA-NSCLC). METHODS AND MATERIALS: Patients with newly diagnosed LA-NSCLC with unresectable stage III disease were recruited between June 2018 and June 2020. Patients were treated with hypo-RT (40 Gy in 10 fractions) followed by hypo-boost (24-28 Gy in 6-7 fractions) combined with concurrent weekly chemotherapy (docetaxel 25 mg/m2 and nedaplatin 25 mg/m2). The primary endpoint of the study was progression-free survival (PFS), and the secondary endpoints included overall survival (OS), locoregional failure-free survival (LRFS), distant metastasis-free survival (DMFS), objective response rate (ORR), and toxicities. RESULTS: From June 2018 to June 2020, 75 patients were enrolled with a median follow-up duration of 28.0 months. The ORR of the whole cohort was 94.7%. Disease progression or death was recorded in 44 (58.7%) patients, with a median PFS of 21.6 months (95% confidence interval [CI], 15.6-27.6 months). The 1- and 2-year PFS rates were 81.3% (95% CI, 72.5%-90.1%) and 43.3% (95% CI, 31.5%-55.1%), respectively. The median OS, DMFS, and LRFS had not been reached at the time of the last follow-up. The 1- and 2-year OS rates were 94.7% (95% CI, 89.6%-99.8%) and 72.4% (95% CI, 62.0%-82.8%), respectively. The most frequent acute nonhematologic toxicity was radiation esophagitis. Grade (G) 2 and G3 acute radiation esophagitis were observed in 20 (26.7%) and 4 (5.3%) patients, respectively. Thirteen patients (13/75, 17.3%) had G2 pneumonitis and no G3-G5 acute pneumonitis occurred during follow-up. CONCLUSIONS: Hypo-RT followed by hypo-boost combined with concurrent weekly chemotherapy could yield satisfactory local control and survival outcomes with moderate radiation-induced toxicity in patients with LA-NSCLC. The new potent hypo-CCRT regimen significantly shortened treatment time and provided the potential opportunity for the combination of consolidative immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsRadiation InjuriesEsophagitisHumansProspective StudiesAntineoplastic Combined Chemotherapy ProtocolsChemoradiotherapy

Autor:innen und Institutionen

  • Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China; State Key Laboratory of Oncology in South China, Guangzhou, China; Collaborative Innovation Center for Cancer Medicine, Sun Yat-s…
  • Department of Cardiac Surgery, First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
  • Pulmonary and Critical Care Medicine, First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.

Zitieren

APA

Zhou, R., Qiu, B., Xiong, M., Liu, Y., Peng, K., Luo, Y., Wang, D., Liu, F., Chen, N., Guo, J., Zhang, J., Huang, X., Rong, Y., & Liu, H. (2023). Hypofractionated Radiotherapy followed by Hypofractionated Boost with weekly concurrent chemotherapy for Unresectable Stage III Non–Small Cell Lung Cancer: Results of A Prospective Phase II Study (GASTO-1049). International Journal of Radiation Oncology*Biology*Physics. https://doi.org/10.1016/j.ijrobp.2023.04.021

Vancouver

Zhou R, Qiu B, Xiong M, Liu Y, Peng K, Luo Y, et al. Hypofractionated Radiotherapy followed by Hypofractionated Boost with weekly concurrent chemotherapy for Unresectable Stage III Non–Small Cell Lung Cancer: Results of A Prospective Phase II Study (GASTO-1049). International Journal of Radiation Oncology*Biology*Physics. 2023. doi:10.1016/j.ijrobp.2023.04.021

BibTeX
@article{Zhou2023,
  author = {Zhou, Rui and Qiu, Bo and Xiong, Mai and Liu, YiMei and Peng, KangQiang and Luo, YiFeng and Wang, DaQuan and Liu, FangJie and Chen, NaiBin and Guo, JinYu and Zhang, Jun and Huang, XiaoYan and Rong, YuMing and Liu, Hui},
  title = {Hypofractionated Radiotherapy followed by Hypofractionated Boost with weekly concurrent chemotherapy for Unresectable Stage III Non–Small Cell Lung Cancer: Results of A Prospective Phase II Study (GASTO-1049)},
  journal = {International Journal of Radiation Oncology*Biology*Physics},
  year = {2023},
  doi = {10.1016/j.ijrobp.2023.04.021}
}
Kostenlos starten →